STUB:NYSEStubHub Holdings, Inc. Analysis
Data as of 2026-05-03 - not real-time
$7.63
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
StubHub is trading at roughly $7.63, well below its 30‑day simple moving average of $6.91 and the 50‑day average of $7.50, but still far under the 200‑day average of $12.58, indicating a long‑term bearish backdrop. Technical momentum shows a bullish MACD histogram (+0.15) and an RSI of 58, suggesting limited downside pressure and a potential short‑term rebound toward the $7.70 resistance zone. Volatility remains high at 56% over the past month and beta is elevated at 1.74, reflecting a stock that moves sharply with market swings. Fundamentally, the company appears deeply undervalued – the discounted cash‑flow model prices the business at $24.35, implying a 62% upside from current levels, and the forward P/E of 5.9 is dramatically below the industry average of 18.9. However, earnings are still negative (trailing EPS –$6.27) and profit margins are in the red, though free cash flow of $0.67 bn and operating cash flow of $0.19 bn provide a cushion. The balance sheet is strained with a debt‑to‑equity ratio near 80% and total debt exceeding cash, adding leverage risk.
Recent material news adds a mixed overlay: a partnership with vivenu promises broader ticket distribution and could lift top‑line growth, while an FTC lawsuit over pricing transparency raises regulatory uncertainty. Analyst sentiment remains supportive (13 analysts averaging a “Buy” with median target $11), but the ongoing legal exposure and high leverage temper enthusiasm. Investors should weigh the sizable upside against the near‑term volatility, regulatory headwinds, and the need for a turnaround in profitability before committing capital.
Recent material news adds a mixed overlay: a partnership with vivenu promises broader ticket distribution and could lift top‑line growth, while an FTC lawsuit over pricing transparency raises regulatory uncertainty. Analyst sentiment remains supportive (13 analysts averaging a “Buy” with median target $11), but the ongoing legal exposure and high leverage temper enthusiasm. Investors should weigh the sizable upside against the near‑term volatility, regulatory headwinds, and the need for a turnaround in profitability before committing capital.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD histogram indicating possible near‑term price lift
- Decreasing volume and bearish longer‑term trend signal caution
- Regulatory uncertainty from the FTC lawsuit
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF‑derived fair value suggests ~62% upside
- Forward EPS turning positive and analyst consensus of “Buy”
- Strategic partnership with vivenu expanding distribution channels
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Long‑term undervaluation relative to industry peers
- Strong free cash flow generation despite current losses
- Potential resolution of FTC case and continued market recovery for live events
Key Metrics & Analysis
Financial Health
Revenue Growth-15.80%
Profit Margin-109.21%
P/E Ratio5.9
ROE-115.61%
ROA-16.09%
Debt/Equity79.89
P/B Ratio2.2
Op. Cash Flow$192.6M
Free Cash Flow$674.9M
Industry P/E18.9
Technical Analysis
TrendBearish
RSI58.0
Support$5.74
Resistance$7.70
MA 20$6.91
MA 50$7.50
MA 200$12.58
MACDBullish
VolumeDecreasing
Fear & Greed Index91.09
Valuation
Fair Value$24.35
Target Price$12.37
Upside/Downside62.06%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.74
Volatility56.40%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.